LX2006 Clinical Data Update
New phase I/II interim clinical data continue to show sustained or deepening improvements across cardiac and neurologic measures of FA, including statistically significant improvement in mean mFARS scores for LX2006-treated participants compared to a propensity-matched control cohort from the UNIFAI natural history study.
Among all participants with 24 months of follow-up (n=11), treatment with LX2006 resulted in a mean improvement of 2.13 points per year, or 4.26 points over two years, on the mFARS scale compared to propensity-matched control.
Among a subset of participants with 36 months of follow-up (n=7), treatment with LX2006 resulted in further improvement, with a mean change of over 4 points relative to baseline
Both neurologic and cardiac measures, including mFARS, left ventricular mass index (LVMI) and troponin, demonstrate durable benefit and continued improvement over time.
